Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01830231 |
|
Recruitment Status : Unknown
Verified January 2014 by Associació per a la Recerca Oncologica, Spain.
Recruitment status was: Recruiting
First Posted : April 12, 2013
Last Update Posted : January 28, 2014
|
Sponsor:
Associació per a la Recerca Oncologica, Spain
Information provided by (Responsible Party):
Associació per a la Recerca Oncologica, Spain
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Due to limited experience with cabazitaxel in TCCU, the study will be started as a randomised phase II study. The aim of the phase II study is to evaluate if the response rates (CR + PR) are sufficiently high to further study the treatment regimens in a phase III setting.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Urothelium Transitional Cell Carcinoma | Drug: Cabazitaxel Drug: Vinflunine | Phase 2 Phase 3 |
Once it is confirmed that the subjects fulfil the eligibility criteria and have signed the informed consent, they will be randomised to receive treatment based on cabazitaxel or vinflunine according to the following study schema:
(Randomize 1:1)
- Cabazitaxel 25 mg/m2 q3w
- Vinflunine 250-320 mg/m2 q3w
Random assignment of treatment will be stratified by the presence of 0 versus 1 of the following unfavourable prognostic risk factors proposed recently by Bellmunt et al. (1):
- Eastern Cooperative Oncology Group (ECOG) PS 1.
- Anaemia with Hb <10 g/dL.
- Presence of liver metastases.
All patients enrolled in the study will receive a cycle of treatment with the study medication (cabazitaxel or vinflunine) every 21 days until disease progression or intolerable/unacceptable toxicity. Tumour evaluations will be scheduled every 6 weeks until progression
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 372 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium |
| Study Start Date : | October 2012 |
| Estimated Primary Completion Date : | November 2016 |
| Estimated Study Completion Date : | November 2016 |
Resource links provided by the National Library of Medicine
Drug Information
available for:
Cabazitaxel
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cabazitaxel
Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
|
Drug: Cabazitaxel
Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
Other Name: Jevtana |
|
Active Comparator: Vinflunine
• Vinflunine will be given intravenously once every 21 days, starting at a dose of:
|
Drug: Vinflunine
Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:
Other Name: Javlor |
Primary Outcome Measures :
- Phase II main objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objective response rate (ORR) of subjects with metastatic or locally advanced previously treated TCCU. [ Time Frame: From date of randomization to disease progression or until 18 months from enrolment. ]Efficacy of cabazitaxel compared to vinflunine on terms of improved objective response rate (ORR)
- Phase III main objective: To assess the efficacy of cabazitaxel compared to vinflunine in terms of improved overall survival (OS) of subjects with metastatic or locally advanced, previously treated TCCU. [ Time Frame: From date of randomization to death from any cause or until 18 months from enrolment. ]
Secondary Outcome Measures :
- Phase II secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved progression-free survival (PFS) and overall survival (OS). [ Time Frame: From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier) ]
- Phase II secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported. [ Time Frame: From the date the informed consent is signed up to 30 days after the last dose. ]
- Phase III secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objetive response rate (ORR) and progression free survival (PFS). [ Time Frame: From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier) ]
- Phase III secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported. [ Time Frame: From the date the informed consent is signed up to 30 days after the last dose. ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent
- Histologically confirmed TCCU (urinary bladder, urethra, ureter or renal pelvis). Patients with mixed histology may be enrolled if TCCU is the predominant component (i.e., > 50% of the histopathology sample) with the exception of neuroendocrine or small cell carcinoma.
- Advanced disease defined as a locally advanced tumour considered unresectable (T4b), node involvement in the inguinal area or above the aortic bifurcation (that are considered to be distant nodes and so metastasis) or metastasis in distant organs.
- Patient should have received one prior platinum-based chemotherapy treatment for locally advanced or stage IV TCCU. Prior platinum-based adjuvant or neoadjuvant therapy is allowed if more than 6 months have elapsed since the end of adjuvant or neoadjuvant therapy till tumour relapse.
- At least one measurable tumour lesion (measurable disease, as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1
- ≥18 years.
- ECOG PS 0 or 1.
-
May have no more than ONE of the following unfavourable risk factors:
- haemoglobin <10 g/dL
- presence of liver metastasis
- ECOG PS 1
- Life expectancy of at least 12 weeks.
- Adequate hematologic, hepatic, and renal function, defined by:
- Females of childbearing potential must have a negative serum pregnancy test within 7 days of study entry.
Exclusion Criteria:
-
Patients that have 2 or more of the following unfavourable risk factors:
- Haemoglobin <10 g/L
- Liver metastasis
- ECOG PS 1.
- Women who are currently pregnant or breast-feeding.
- Any unresolved non-hematologic Adverse Event (AE) grade >1 (Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) Version 4.0) from previous anti-cancer therapy (other than alopecia)
- Patients who had undergone major surgery, radiation therapy or treatment with chemotherapy or any investigational agent within 28 days prior to Study day 1.
- Evidence of severe or uncontrolled systemic disease or any concurrent condition
- History of another neoplasm.
- History of hypersensitivity reactions to taxanes (docetaxel) (cabazitaxel specific criteria), vinca alkaloids (vinflunine specific criteria) or to any of the formulation excipients, including polysorbate 80
- clear evidence or symptoms of central nervous system metastasis (cabazitaxel specific criteria).
- Clinically significant cardiac condition
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01830231
Contacts
| Contact: Joaquim Bellmunt, MD/PhD | +34 93 2483137 | jbellmunt@parcdesalutmar.cat | |
| Contact: Inmaculada Musté | +34 93 2483137 | oncologia.apro@gmail.com |
Locations
Show 20 study locations
Sponsors and Collaborators
Associació per a la Recerca Oncologica, Spain
Investigators
| Principal Investigator: | Joaquim Bellmunt, MD/PhD | APRO |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Associació per a la Recerca Oncologica, Spain |
| ClinicalTrials.gov Identifier: | NCT01830231 |
| Other Study ID Numbers: |
Secavin-12 |
| First Posted: | April 12, 2013 Key Record Dates |
| Last Update Posted: | January 28, 2014 |
| Last Verified: | January 2014 |
Keywords provided by Associació per a la Recerca Oncologica, Spain:
|
TCCU Vinflunine Cabazitaxel Metastatic Locally advance |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Transitional Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |